Clinical Data Novartis reveals more data behind Pluvicto expansion bid PharmaphorumNovartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.OncologyRead full story pharminent May 18, 2026 (Last updated: May 18, 2026) Pharmaphorum Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Regeneron immunotherapy combo comes up short in melanoma trialNext: AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
